Comparing the current results to its competitors, Regeneron Pharmaceuticals Inc reported Revenue increase in the 1 quarter 2026 by 19.04 % year on year. The revenue growth was below Regeneron Pharmaceuticals Inc 's competitors' average revenue growth of 19.5 %, achieved in the same quarter.
Regeneron Pharmaceuticals Inc Net Income in the 1 quarter 2026 fell year on year by -10.08%, while most of its competitors have experienced a contraction in net income by -38.11 %.
April 22, 2025
Regeneron Pharmaceuticals, Inc. has recently announced a significant investment aimed at bolstering its manufacturing capacities for its leading biologic medicines through a new agreement with FUJIFILM Diosynth Biotechnologies in North Carolina. This strategic partnership not only positions Regeneron to increase its production capabilities but also signifies a commitment to create high-paying jobs in the region, fostering an environment conducive to innovation and economic growth.The agreement with FUJIFILM Diosynth, a recognized leader in biotechnological manufacturing, is expected to enhance the supply chain effectiveness for Regeneron’s biologic medicines. This is particularly critical as the demand for...
February 28, 2025
Advances in Oncology: Linvoseltamab, EYLEA HD, and Odronextamab Signal New Era in Treatments for Refractory Conditions In an era marked by rapid advancements in pharmaceutical innovations, targeted treatments for refractory oncology conditions represent a significant shift in clinical practice, providing hope where options were previously limited. Recently, Regeneron Pharmaceuticals, Inc. has been at the forefront, announcing significant advancements across its portfolio. This article explores the latest developments with linvoseltamab, EYLEA HD, and odronextamab, highlighting their potential to revolutionize treatment paradigms in their respective domains. Linvoseltamab: A Beacon of Hope for Refractory Mul...
February 24, 2025
Regeneron Pharmaceuticals: Navigating Legal Challenges Amid Impressive Revenue Growth In the intricate landscape of the pharmaceutical industry, Regeneron Pharmaceuticals, Inc. has emerged as a notable player, despite facing recent legal challenges. As of February 2025, Levi and Korsinsky, LLP announced a securities class action lawsuit against Regeneron (NASDAQ: REGN), focusing on the interests of its shareholders. This lawsuit signifies a critical juncture for the company, potentially influencing shareholder sentiment and corporate reputation in the volatile pharmaceutical market.Amidst these legal proceedings, Regeneron continues to demonstrate remarkable financial resilience and competitive prowess, high...
December 9, 2024
The pharmaceutical landscape continues to evolve rapidly, particularly in the field of oncology, where novel therapies seek to improve outcomes for patients battling various forms of cancer. A notable development is the emergence of odronextamab, a bispecific T-cell engaging antibody that has recently demonstrated remarkable efficacy in treating follicular lymphoma (FL). Initial results from the safety lead-in portion of the confirmatory Phase 3 OLYMPIA-1 trial highlighted a concerning trend: odronextamab monotherapy led to complete responses in all evaluable patients with previously untreated FL. This promising data comes at a time when Regeneron Pharmaceuticals Inc. the company behind odronextamab, is nav...
November 13, 2024
As the biopharmaceutical industry continues to evolve, Regeneron Pharmaceuticals is at the forefront of innovation, evidenced by their robust pipeline advancements spanning multiple modalities and conditions. At the upcoming American Society of Hematology (ASH) Annual Meeting, Regeneron is poised to highlight significant developments across 10 types of blood cancers and disorders. Among these updates, the company will present compelling data on a novel investigational combination therapy and unveil groundbreaking collaborations that promise to reshape gene editing technologies for a variety of diseases. Unveiling Pioneering Data in Blood DisordersAt the ASH meeting, Regeneron will present head-to-head result...
September 9, 2024
Libtayo (Cemiplimab): A Beacon of Hope in Advanced Non-Small Cell Lung Cancer Five-Year Survival Data Illuminate the Path ForwardIn the ever-evolving landscape of oncology, where breakthroughs are pivotal, Libtayo (cemiplimab) has emerged as a beacon of hope for patients grappling with advanced non-small cell lung cancer (NSCLC). Recently presented late-breaking data at the World Conference on Lung Cancer (WCLC) reaffirmed the potency of this innovative immunotherapy. The findings revealed that Libtayo monotherapy has nearly doubled the median overall survival rates for patients, while also demonstrating impressive reductions in both the risk of death and the progression of the disease specifically by 41%...
May 28, 2024
In a development that has caught the attention of investors and stakeholders alike, Pomerantz LLP has launched an investigation into potential claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). The investigation is probing the company s practices, seeking to ascertain whether any actions taken by Regeneron could have adversely affected its shareholders. This unfolding situation raises significant questions about corporate governance and investor protection, topics that are increasingly critical in today s investment landscape.Pomerantz LLP, a firm renowned for its prowess in class action and investor rights litigation, made the announcement on May 28, 2024. Regeneron Pharmaceuti...
May 23, 2024
Innovative Therapeutic Approaches Show Promising Results in Oncology, Genetic Deafness, and Retinal Diseases The landscape of therapeutic interventions is witnessing groundbreaking advancements in the treatment of challenging diseases. Recent presentations at prominent medical conferences have highlighted important findings from clinical trials involving novel therapies for microsatellite stable colorectal cancer, genetic deafness, and severe retinal diseases. This article delves into the promising data on the bispecific antibody REGN7075 combined with Libtayo® (cemiplimab), the gene therapy DB-OTO for genetic deafness, and EYLEA® HD (aflibercept) for retinal conditions. Advancements in Oncology: REGN7075...
May 13, 2024
In the burgeoning landscape of pharmaceutical science, novel treatments continue to demonstrate potential in managing and treating a variety of conditions, from chronic respiratory diseases to retinal anomalies, and even cancer. An array of pharmaceutical companies like Regeneron are driving the industry forward with advanced treatment methods, two of which are Dupixent and EYLEA HD.Dupixent (dupilumab), as disclosed by Regeneron, has recently been accepted for Priority Review by the U.S Food and Drug Administration (FDA) for potential treatment of chronically affected adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP). This approval would make Dupixent the first pharmaceutical treatment i...
March 11, 2024
In a significant development, the US Food and Drug Administration (FDA) has expanded its approval of Praluent (alirocumab) injection to include children aged 8 years and older who suffer from heterozygous familial hypercholesterolemia (HeFH), a genetic form of high cholesterol. This breakthrough in treatment options offers hope to the younger population grappling with this potentially life-threatening condition.Praluent, a powerful and innovative therapy manufactured by a leading pharmaceutical company, has demonstrated its efficacy in lowering cholesterol levels in the adult population. Now, with the FDA s approval, children with HeFH can also benefit from this groundbreaking treatment, providing them with ...
Publicly Traded Peers of Regeneron Pharmaceuticals Inc
Mesoblast Limited Share Performance
+0.72%
Over The Past 5 Days
Mesoblast Limited
Profile
Mesoblast Ltd is a biotechnology company that operates on a business model focused on the development and commercialization of proprietary cell-based regenerative medicines. They aim to transform the treatment of various degenerative diseases by utilizing their patented technology and strategic partnerships with pharmaceutical companies.
Merck & Co. Inc. operates primarily as a research-driven pharmaceutical company, focused on the development, manufacturing, and marketing of prescription drugs and vaccines globally. It aims to address unmet medical needs through innovative research, collaborations, and rigorous clinical trials, while promoting patient well-being and contributing to global healthcare with high-quality, affordable medications.
Matinas Biopharma Holdings Inc operates as a clinical-stage biopharmaceutical company. Their business model centers around developing therapeutics through the utilization of lipid nano-crystal (LNC) platform technologies. These technologies enable the effective delivery of drugs to improve patient outcomes in various diseases and conditions such as fungal infections, viral infections, and cancer.
Maxcyte Inc's business model revolves around providing cell engineering and flow electroporation technology to facilitate drug discovery, development, and manufacturing processes.
Sources:
Regeneron Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Regeneron Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
